• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Kilitch Share Price

    Kilitch Drugs(I) Share PriceKilitch Drugs(I)

    Small Cap 6.2k Result
    ₹349.65
    -7.1 (-1.99%)
    As on 10 December, 2023 | 22:35 BSE: 524500 NSE: KILITCHISIN: INE729D01010

    Kilitch Drugs(I) Performance

    Day Range

    • Low 349.65
    • High 349.65
    ₹ 349.65

    52 Week Range

    • Low 125.00
    • High 364.25
    ₹ 349.65
    • Open Price0.00
    • Previous Close356.75
    • Volume2407

    Start SIP in Kilitch Drugs(I)

    Start SIP

    Kilitch Drugs(I) Share Price

    • Over 1 Month 12.32%
    • Over 3 Month 69.73%
    • Over 6 Month 69.24%
    • Over 1 Year 116.7%

    Kilitch Drugs(I) Key Statistics

    P/E Ratio 40.1
    PEG Ratio 0.6
    Market Cap Cr 562
    Price to Book Ratio 3.7
    EPS 9.3
    Dividend 0
    Relative Strength Index 74.23
    Money Flow Index 86.41
    MACD Signal 15.82
    Average True Range 6.75

    Kilitch Drugs(I) Investment Rating

    • Master Rating:

    • Kilitch Drugs India has an operating revenue of Rs. 153.21 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 9% is okay, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 64% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 97 which is a GREAT score indicating consistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Kilitch Drugs(I) Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 32314329222432
    Operating Expenses Qtr Cr 26263724192028
    Operating Profit Qtr Cr 6574334
    Depreciation Qtr Cr 0000000
    Interest Qtr Cr 0000000
    Tax Qtr Cr 2121011
    Net Profit Qtr Cr 4454433
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 122110
    Operating Expenses Annual Cr 10194
    Operating Profit Annual in Cr 1711
    Depreciation Cr 11
    Interest Annual Cr 11
    Tax Annual Cr 43
    Net Profit Annual Cr 1611
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 65
    Cash from Investing Activity Annual Cr 6-16
    Cash from Financing Annual Activity Cr 38
    Net Cash Flow Annual Cr 15-3
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 196178
    Fixed Assets Annual Cr 1614
    Total Non Current Assets Annual Cr 138135
    Total Current Assets Annual Cr 11598
    Total Assets Annual Cr 252232
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 126114
    ROE Annual % 86
    ROCE Annual % 108
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1815
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 41374530313337
    Operating Expenses Qtr Cr 33303926273032
    Operating Profit Qtr Cr 9664435
    Depreciation Qtr Cr 1111111
    Interest Qtr Cr 2111211
    Tax Qtr Cr 2121011
    Net Profit Qtr Cr 5342223
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 143117
    Operating Expenses Annual Cr 122104
    Operating Profit Annual in Cr 1810
    Depreciation Cr 42
    Interest Annual Cr 51
    Tax Annual Cr 43
    Net Profit Annual Cr 107
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 36
    Cash from Investing Activity Annual Cr 8-15
    Cash from Financing Annual Activity Cr -17
    Net Cash Flow Annual Cr 10-2
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 152139
    Fixed Assets Annual Cr 6847
    Total Non Current Assets Annual Cr 9396
    Total Current Assets Annual Cr 126114
    Total Assets Annual Cr 220210
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 9790
    ROE Annual % 75
    ROCE Annual % 118
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1512
    Invest in Kilitch Drugs(I)

    Kilitch Drugs(I) Technicals

    EMA & SMA

    Current Price
    ₹349.65
    -7.1 (-1.99%)
    pointer
    • Bullish Moving Average
    • ___
    • 15
    • Bearish Moving Average
    • ___
    • 1
    • 20 Day
    • ₹330.19
    • 50 Day
    • ₹298.76
    • 100 Day
    • ₹264.84
    • 200 Day
    • ₹230.89
    • 20 Day
    • ₹331.66
    • 50 Day
    • ₹295.24
    • 100 Day
    • ₹247.21
    • 200 Day
    • ₹212.40

    Kilitch Drugs(I) Resistance and Support

    PIVOT
    ₹349.65
    Resistance
    First Resistance 349.65
    Second Resistance 349.65
    Third Resistance 349.65
    RSI 74.23
    MFI 86.41
    MACD Single Line 15.82
    MACD 16.49
    Support
    First Resistance 349.65
    Second Resistance 349.65
    Third Resistance 349.65

    Kilitch Drugs(I) Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 4,175 417,500 100
    Week 14,337 1,433,740 100
    1 Month 16,741 1,674,105 100
    6 Month 14,782 1,478,237 100

    Kilitch Drugs(I) Result Highlights

    Kilitch Drugs(I) Synopsis

    NSE-Medical-Diversified

    Kilitch Drugs(I) is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 117.78 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2023. Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718.
    Market Cap 562
    Sales 134
    Shares in Float 0.50
    No of funds 1
    Yield 0.51
    Book Value 2.78
    U/D Vol ratio 2.3
    LTDebt / Equity
    Alpha 0.34
    Beta 0.6

    Kilitch Drugs(I)

    Owner NameSep-23Jul-23Jun-23Mar-23
    Promoters 69.23%69.23%68.25%68.25%
    Mutual Funds
    Insurance Companies
    Foreign Portfolio Investors
    Financial Institutions/ Banks
    Individual Investors 26.13%26.5%27.4%27.49%
    Others 4.64%4.27%4.35%4.26%

    Kilitch Drugs(I) Management

    Name Designation
    Mr. Mukund P Mehta Managing Director
    Mr. Bhavin Mukund Mehta Whole Time Director
    Mrs. Mira B Mehta Whole Time Director
    Mr. Hemang Engineer Independent Director
    Mr. Venkita Subramanian Rajan Independent Director
    Prof. Vasudev Krishna Murti Independent Director

    Kilitch Drugs(I) Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Kilitch Drugs(I) Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-08-11 Quarterly Results
    2023-07-22 Others To consider and approve conversion of warrants into the equity shares of the Company to the specified person only. per share(5%)Final Dividend
    2023-05-29 Audited Results
    2023-02-14 Quarterly Results

    Kilitch Drugs(I) FAQs

    What is Share Price of Kilitch Drugs(I) ?

    Kilitch Drugs(I) share price is ₹349 As on 10 December, 2023 | 22:21

    What is the Market Cap of Kilitch Drugs(I) ?

    The Market Cap of Kilitch Drugs(I) is ₹562.3 Cr As on 10 December, 2023 | 22:21

    What is the P/E ratio of Kilitch Drugs(I) ?

    The P/E ratio of Kilitch Drugs(I) is 40.1 As on 10 December, 2023 | 22:21

    What is the PB ratio of Kilitch Drugs(I) ?

    The PB ratio of Kilitch Drugs(I) is 3.7 As on 10 December, 2023 | 22:21

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.